Migraine Epidemiology, Diagnosis, and Preventive Gaps
Formal criteria for diagnosis.
Migraine Essentials
Migraine Essentials is a resource for primary care physicians, PAs and NPs as well as consumers looking for authoritative insights into the diagnosis, treatment , and challenges of migraine disease.
Migraine Essentials are intended to be short and to the point text and audio content addressing a variety of issues in migraine disease not typically found in mainstream didactic CME, including the use of alternative treatments. Migraine Essentials is intended to compliment conventional CME, not replace it.
Butterbur Petasin is a standardized proprietary extract manufactured by Weber & Weber International, Germany, and forms the basis of all peer-reviewed pre-clinical and clinical research published to date.
Proprietary Butterbur Petasin: Petasites hybridus Extract
Proprietary Butterbur Petasin serves as a rigorously tested, non-prescription preventive treatment for patients with episodic migraine.
Pathophysiologic Targets in Migraine: Proprietary Butterbur Petasin® Mechanisms
Proprietary Butterbur Petasin exerts multimodal effects across key migraine pathophysiologic pathways.
CGRP Suppression via TRP Channel Modulation
Proprietary Butterbur Petasin significantly suppresses CGRP release in both the dura mater and trigeminal ganglion in a dose-dependent manner.
Randomized Controlled Trial #1 in Episodic Migraine (Adult)
Proprietary Butterbur Petasin significantly reduced migraine frequency from 3.4 to 1.8 attacks per month, compared with a smaller decrease from 2.9 to 2.6 in the placebo group.
Randomized Controlled Trial #2 in Episodic Migraine (Adult)
Proprietary Butterbur Petasin offers a clinically meaningful preventive option for adults with episodic migraine.
Randomized Controlled Trials in Episodic Migraine (Pediatric)
Seventy-seven percent achieved a ≥50% reduction in attack frequency, with an overall 63% reduction from baseline.
Safety Profile – Preclinical Toxicity Studies
Proprietary Butterbur Petasin demonstrated no clinically relevant hepatotoxicity, even with prolonged or high-dose exposure.
Proprietary Butterbur Petasin Safety Profile: 24 Years of Pharmacovigilance and Causality Assessment
Exposure reached ~2.674 million patient-months worldwide, including ~2.04 million in US/Canada without any hepatobiliary AE reports in the latter region.
Proprietary Butterbur Petasin vs Competitors: Superior Potency and PA-Free Safety
21 commercially available butterbur supplements were analyzed.
Third Party Lab Reports of Fraudulent Butterbur Brands
Two batch results by independent ISO 17025 laboratories
Proprietary Butterbur Petasin in Clinical Practice: Ideal Candidates & Contraindications
Proprietary Butterbur Petasin is an evidence-based migraine preventive with a strong safety profile, contraindicated in pregnancy/lactation, liver disease, and Asteraceae allergies.